ClinicalTrials.gg
CompletedNCT03849404Updated Jul 28, 2020

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of Adalimumab in Plaque Psoriasis, sponsored by Alvotech Swiss AG. Completed at 20 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-28.

Sponsored by Alvotech Swiss AG · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
10th of 48
413 · median 148
Started
2019
the only one that year
Phase 3
26 of 48
1 open now
Registered
38th of 48
by date
Lead sponsor
2 of 48
Alvotech Swiss AG

Among the 48 studies testing adalimumab in Psoriasis, this one is the 10th largest by enrollment, is the only one that started in 2019, is one of 26 in phase 3, and was the 38th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

Safety and Efficacy study of AVT02 (Alvotech Biosimilar to Adalimumab), in patients with moderate to severe plaque psoriasis.

Read the detailed description

A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira® in Patients with Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS).

This study will be conducted at about 40 study centers in central and eastern European countries. A contract research organization, will oversee operational aspects of this study on behalf of Alvotech Swiss AG (Alvotech), the Sponsor of the study.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with moderate-to-severe chronic plaque psoriasis who has involved body surface area (BSA) ≥ 10% (Palm Method), ≥ 12 on the PASI, and static Physicians Global Assessments (sPGA) ≥ 3 (moderate) at Screening and at BL.
  • Patient has had stable psoriatic disease for at least 2 months (ie, without significant changes as defined by the Investigator or designee).
  • Patient is a candidate for systemic therapy and the patient has a previous failure, inadequate response, intolerance, or to at least 1 systemic antipsoriatic therapy including, but not limited to, methotrexate, cyclosporine, psoralen plus ultraviolet light A (PUVA), and ultraviolet light B (UVB).

Exclusion criteria

Exclusion Criteria:

  • Patient has prior use of 2 or more biologics for treatment of PsO.
  • Patient diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (eg, eczema), or other systemic disorder inflammatory disease at the time of the Screening visit that would interfere with evaluations of the effect of the study drug on psoriasis.
  • Patient has prior use of any of the following medications within specified time periods or will require use during the study:

    1. Topical medications within 2 weeks of BL (Week 1).
    2. PUVA phototherapy and/or UVB phototherapy within 4 weeks prior to the BL Visit.
    3. Nonbiologic psoriasis systemic therapies (eg, cyclosporine, methotrexate, and acitretin) within 4 weeks prior to the BL Visit.
    4. Any prior or concomitant or biosimilar adalimumab therapy, either approved or .
    5. Any systemic in the 4 weeks prior to BL.

Note: Only key inclusion/exclusion criteria mentioned here. Patients will be screened and randomized per the list in the protocol

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
413 participants (actual)

Study arms

  • Experimental
    AVT02 100mg/mL (Adalimumab Biosimilar)

    Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48

    Biological: Adalimumab

  • Experimental
    EU-Humira 100mg/mL (Adalimumab Originator)

    Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48

06

What researchers measure

Primary outcomes

  1. Psoriasis Area and Severity Index (PASI)

    Percent (%) change in Psoriasis Area and Severity Index (PASI)

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Psoriasis Area and Severity Index (PASI)

    Percent (%) change in Psoriasis Area and Severity Index (PASI)

    Time frame: Percent improvement in PASI from BL to Week 8, 12, 24, 32, 42, and 50

07

Study locations

20 sites
  • North Estonia Medical Centre Foundation, Dermatovenerology Centre
    Tallinn, 13419, Estonia
  • Innomedica OU
    Tallin, 10117, Estonia
  • OU Vahlberg & Pild
    Tallin, 10134, Estonia
  • Tartu University Hospital, Dermatology Clinic
    Tartu, 50406, Estonia
  • Aleksandre Aladashvili Clinic LLC
    Tbilisi, 0102, Georgia
  • The first University Clinic of Tbilisi State Medical University
    Tbilisi, 0141, Georgia
  • Scientific Research National Center of Dermatology and Venereology LLC
    Tbilisi, 0159, Georgia
  • Health Institute LLC
    Tbilisi, 0160, Georgia
  • David Abuladze Georgian-Italian Clinic LTD
    Tbilisi, 0179, Georgia
  • ClinicMed Daniluk, Nowak Spółka Jawna
    Białystok, Poland
  • NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik
    Białystok, Poland
  • Centrum Badań Klinicznych PI-House Sp. Z o.o.
    Gdańsk, 80-546, Poland
  • Synexus Polska Sp. z o.o. Oddział w Gdańsku
    Gdańsk, Poland
  • Center Med Kraków Sp. Z o.o.
    Kraków, Poland
  • NZOZ "Nasz Lekarz" Sławomir Jeka, Praktyka Grupowa Lekarzy Rodzinnych z Przychodnią Specjalistyczną
    Toruń, Poland
  • Synexus Polska Sp. z o.o.Oddział w Warszawie
    Warsaw, Poland
  • DermMedica Sp. z o.o.
    Wrocław, Poland
  • Synexus Polska Sp. z o.o. Oddział we Wrocławiu
    Wrocław, Poland
  • Centrum Medyczna ALL-MED
    Łódź, Poland
  • Zaporizhzhya Regional Dermatology and Venereology Clinical Dispensary
    Zaporizhzhya, Ukraine
08

References and documents

Publications

  • Feldman SR, Reznichenko N, Pulka G, Kingo K, George Galdava, Berti F, Sobierska J, Dias R, Guenzi E, Hendrik Otto, Haliduola HN, Kay R, Stroissnig H. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study. BioDrugs. 2021 Nov;35(6):735-748. doi: 10.1007/s40259-021-00502-w. Epub 2021 Oct 16. PubMed 34657274 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Dec 2019, 10 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2019
First posted
Feb 21, 2019
StartActual
Feb 20, 2019
Primary completionActual
Dec 23, 2019
CompletionActual
Jul 20, 2020
Last update
Jul 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03849404
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
Feb 21, 2019
Start date
Feb 20, 2019
Primary completion
Dec 23, 2019
Completion
Jul 20, 2020
Last update
Jul 28, 2020

Study contacts

Steven Feldman, MD, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion